# Lucentis for New Onset Neovascular Glaucoma

> **NCT00727038** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University of Illinois at Chicago**

## Conditions studied

- Glaucoma
- New Onset Glaucoma
- Neovascular Glaucoma
- New Onset Neovascular Glaucoma

## Interventions

- **DRUG:** Ranibizumab (Lucentis)

## Key facts

- **NCT ID:** NCT00727038
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-01-04
- **Primary completion:** 2009-05-15
- **Final completion:** 2009-05-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company withdrew funding/sponsorship
- **Last updated:** 2020-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00727038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00727038, "Lucentis for New Onset Neovascular Glaucoma". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00727038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*